Pfizer to Acquire Metsera in $4.9B Deal Expanding Obesity Pipeline

Published on LinkedIn (via Spencer Knight)

Pfizer announced plans to acquire Metsera for up to $4.9B, adding GLP-1 and amylin-based therapies to its obesity portfolio. The move positions Pfizer directly against Lilly and Novo as competition in metabolic innovation intensifies.

👉 Read the full article: Pfizer to acquire Metsera for $4.9Billion

Disclaimer

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link. SSCTR does not provide medical advice, and the views expressed are for educational purposes only.